192 related articles for article (PubMed ID: 15142263)
1. The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Palmer G; Burger D; Mezin F; Magne D; Gabay C; Dayer JM; Guerne PA
Arthritis Res Ther; 2004; 6(3):R181-9. PubMed ID: 15142263
[TBL] [Abstract][Full Text] [Related]
2. The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Magne D; Mézin F; Palmer G; Guerne PA
Inflamm Res; 2006 Nov; 55(11):469-75. PubMed ID: 17122964
[TBL] [Abstract][Full Text] [Related]
3. The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Moon SJ; Kim EK; Jhun JY; Lee HJ; Lee WS; Park SH; Cho ML; Min JK
J Transl Med; 2017 Feb; 15(1):31. PubMed ID: 28193225
[TBL] [Abstract][Full Text] [Related]
4. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Vergne-Salle P; Léger DY; Bertin P; Trèves R; Beneytout JL; Liagre B
Cytokine; 2005 Sep; 31(5):335-48. PubMed ID: 16099671
[TBL] [Abstract][Full Text] [Related]
5. Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.
Migita K; Miyashita T; Ishibashi H; Maeda Y; Nakamura M; Yatsuhashi H; Ida H; Kawakami A; Aoyagi T; Kawabe Y; Eguchi K
Clin Exp Immunol; 2004 Sep; 137(3):612-6. PubMed ID: 15320915
[TBL] [Abstract][Full Text] [Related]
6. The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E(2), matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes.
Burger D; Begué-Pastor N; Benavent S; Gruaz L; Kaufmann MT; Chicheportiche R; Dayer JM
Rheumatology (Oxford); 2003 Jan; 42(1):89-96. PubMed ID: 12509619
[TBL] [Abstract][Full Text] [Related]
7. Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis.
Cutolo M; Sulli A; Ghiorzo P; Pizzorni C; Craviotto C; Villaggio B
Ann Rheum Dis; 2003 Apr; 62(4):297-302. PubMed ID: 12634225
[TBL] [Abstract][Full Text] [Related]
8. Mast cell activation and its relation to proinflammatory cytokine production in the rheumatoid lesion.
Woolley DE; Tetlow LC
Arthritis Res; 2000; 2(1):65-74. PubMed ID: 11219391
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of the antiproliferative action of leflunomide. A77 1726, the active metabolite of leflunomide, does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides.
Cao WW; Kao PN; Chao AC; Gardner P; Ng J; Morris RE
J Heart Lung Transplant; 1995; 14(6 Pt 1):1016-30. PubMed ID: 8719445
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.
Miljkovic Dj; Samardzic T; Drakulic D; Stosic-Grujicic S; Trajkovic V
Cytokine; 2002 Aug; 19(4):181-6. PubMed ID: 12297111
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture.
Ju DW; Zheng QY; Wang HB; Fang J
Zhongguo Yao Li Xue Bao; 1994 May; 15(3):223-6. PubMed ID: 7976375
[TBL] [Abstract][Full Text] [Related]
12. The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Vrenken TE; Buist-Homan M; Kalsbeek AJ; Faber KN; Moshage H
J Hepatol; 2008 Nov; 49(5):799-809. PubMed ID: 18809221
[TBL] [Abstract][Full Text] [Related]
13. Interferon beta stimulates interleukin 1 receptor antagonist production in human articular chondrocytes and synovial fibroblasts.
Palmer G; Mezin F; Juge-Aubry CE; Plater-Zyberk C; Gabay C; Guerne PA
Ann Rheum Dis; 2004 Jan; 63(1):43-9. PubMed ID: 14672890
[TBL] [Abstract][Full Text] [Related]
14. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Kirsch BM; Zeyda M; Stuhlmeier K; Grisar J; Smolen JS; Watschinger B; Stulnig TM; Hörl WH; Zlabinger GJ; Säemann MD
Arthritis Res Ther; 2005; 7(3):R694-703. PubMed ID: 15899055
[TBL] [Abstract][Full Text] [Related]
15. Leflunomide and malononitrilamides.
Silva Júnior HT; Morris RE
Am J Med Sci; 1997 May; 313(5):289-301. PubMed ID: 9145039
[TBL] [Abstract][Full Text] [Related]
16. Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures.
Elkayam O; Yaron I; Shirazi I; Judovitch R; Caspi D; Yaron M
Ann Rheum Dis; 2003 May; 62(5):440-3. PubMed ID: 12695157
[TBL] [Abstract][Full Text] [Related]
17. Production of intracellular IL-1alpha, IL-1beta, and IL-1Ra isoforms by activated human dermal and synovial fibroblasts: phenotypic differences between human dermal and synovial fibroblasts.
Maret M; Chicheportiche R; Dayer JM; Gabay C
Cytokine; 2004 Mar; 25(5):193-203. PubMed ID: 15036245
[TBL] [Abstract][Full Text] [Related]
18. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Chong AS; Huang W; Liu W; Luo J; Shen J; Xu W; Ma L; Blinder L; Xiao F; Xu X; Clardy C; Foster P; Williams JA
Transplantation; 1999 Jul; 68(1):100-9. PubMed ID: 10428276
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Doscas ME; Williamson AJ; Usha L; Bogachkov Y; Rao GS; Xiao F; Wang Y; Ruby C; Kaufman H; Zhou J; Williams JW; Li Y; Xu X
Neoplasia; 2014 Oct; 16(10):824-34. PubMed ID: 25379019
[TBL] [Abstract][Full Text] [Related]
20. Production of interleukin-1 receptor antagonist by human articular chondrocytes.
Palmer G; Guerne PA; Mezin F; Maret M; Guicheux J; Goldring MB; Gabay C
Arthritis Res; 2002; 4(3):226-31. PubMed ID: 12010575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
